✦ LIBER ✦

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

✍ Scribed by Sonneveld, P.; Schmidt-Wolf, I. G. H.; van der Holt, B.; el Jarari, L.; Bertsch, U.; Salwender, H.; Zweegman, S.; Vellenga, E.; Broyl, A.; Blau, I. W.; Weisel, K. C.; Wittebol, S.; Bos, G. M. J.; Stevens-Kroef, M.; Scheid, C.; Pfreundschuh, M.; Hose, D.; Jauch, A.; van der Velde, H.; Raymakers, R.; Schaafsma, M. R.; Kersten, M.-J.; van Marwijk-Kooy, M.; Duehrsen, U.; Lindemann, W.; Wijermans, P. W.; Lokhorst, H. M.; Goldschmidt, H. M.

Book ID: 118745586
Publisher: American Society of Clinical Oncology
Year: 2012
Tongue: English
Weight: 232 KB
Volume: 30
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2011.39.6820

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

B152 First Analysis of HOVON-65/GMMG-HD4

B152 First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

✍ Sonneveld, P; Eljarari, L; Salwender, H; Zweegman, S; Vellenga, E; Van Der Holt, 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 116 KB

Mechanisms of peripheral neuropathy asso

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

✍ Annemiek Broyl; Sophie L Corthals; Joost LM Jongen; Bronno van der Holt; Rowan K 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 125 KB

Joint HOVON-50/GMMG-HD3 randomized trial

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

✍ H. Goldschmidt; P. Sonneveld; F.W. Cremer; B. Holt; P. Westveer; I. Breitkreutz; 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 138 KB

Treatment of Bendamustine and Prednisone

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachs 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 344 KB

Prognostic significance of the S-phase f

Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486

✍ Trendle, M.C.; Leong, T.; Kyle, R.A.; Katzmann, J.A.; Oken, M.M.; Kay, N.E.; Van 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well-established independent prognostic factor for patients with newly diagnosed multiple myeloma, but the test is not easily done in most laboratories. The purpose of this study was to determine if the pr